Safety profile of ultrasmall superparamagnetic iron oxide ferumoxtran- 10: Phase II clinical trial data

Journal of Magnetic Resonance Imaging

Volumn 9, Issue 2, 1999, Pages 291-294

  Sharma, Raju ^a   Saini, Sanjay ^a   Ros, Pablo R ^b   Hahn, Peter F ^a   Small, William C ^c   De Lange, Eduard E ^d   Stillman, Arthur E ^e   Edelman, Robert R ^f   Runge, Val M ^g   Outwater, Eric K ^h   Morris, Marie ⁱ   Lucas, Maria ⁱ  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Imaging Center   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g UNIVERSITY OF KENTUCKY   (United States)

^h THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

ⁱ Advanced Magnetics Inc   (United States)

Author keywords

Contrast medium; Iron oxides; MR imaging; Safety

Indexed keywords

FERUMOXTRAN 10; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG SAFETY; DYSPNEA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SPLEEN; THORAX PAIN;

EID: 0033007861     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1522-2586(199902)9:2<291::aid-jmri21>3.0.co;2-%23     Document Type: Article

References (8)

1. Weissleder R. Liver MR imaging with iron oxides: toward consensus and clinical practice. Radiology 1994;193:593-595.
2. McLachlan SJ, Morris MR, Lucas MA, et al. Phase I clinical evaluation of a new iron oxide MR contrast agent. J Magn Reson Imaging 1994;4:301-307.
3. Hahn PF, Saini S. Liver-specific MR imaging contrast agents. Radiol Clin North Am 1998;36:287-297.
4. Jung CW. Surface properties of superparamagnetic iron oxide contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging 1995;13:675-691.
5. Jung CW, Jacobs P. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging 1995;13:661-674.
6. Saini S, Edelman RR, Sharma P. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227). AJR 1995;164:1147-1152.
7. Ros PR, Freeny PC, Harms SE et al. Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 1995;196:481-488.
8. Bellin MF, Roy C, Kinkel K, et al. Lymph node metastasis: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles - initial clinical experience. Radiology 1998;207:799-808.